August 2012
-
GlaxoSmithKline and Innoviva have announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the 100/25 mcg strength of the Relvar Ellipta fluticasone furoate/vilanterol DPI for the treatment of COPD. Both the… Read more . . .
-
Aradigm Corporation has announced that top-line results from the Phase 3 ORBIT-3 and ORBIT-4 trials of Pulmaquin inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in patients with non-cystic fibrosis bronchiectasis (non-CF BE)… Read more . . .
-
Intertek has announced the addition of morphologically-directed Raman spectroscopy (MDRS) capabilities to its OINDP analytical and development services with the acquisition of a Malvern Instruments Morphologi G3-ID. MDRS has the ability to distinguish API particle… Read more . . .
-
Avanir Pharmaceuticals, which launched its Onzetra Xsail intranasal dry powder sumatriptan in the US in May 2016, has announced the appointment of Richard Malamut as Senior VP, Research and Development and Chief Medical Officer. Malamut… Read more . . .
-
Teva Israel and Syqe Medical have announced that Teva will distribute Syqe’s cannabis inhaler in Israel, with Syqe responsible for manufacturing the inhaler and cartridges. No financial terms were disclosed. The Syqe device delivers 100… Read more . . .
-
Device developer Merxin has announced the availability of its MRX001 “off the shelf” multidose dry powder inhaler. According to an announcement on the website of Merxin sister company Aedestra, the blister-based DPI is designed for… Read more . . .
-
GlaxoSmithKline has submitted an NDA in the US for its fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) dry powder inhaler for the treatment of COPD, according to an announcement from GSK and Innoviva. The product will be… Read more . . .
-
On November 14, 2016, Judge Sue Robinson of the US District Court for the District of Delaware issued a ruling upholding Merck’s US patent 6,127,353 but finding that Teva’s mometasone nasal spray ANDA does not… Read more . . .
-
Results from a study of Adherium’s Smartinhaler adherence monitoring system showing a 5-fold reduction in hospitalizations over a one-year period for children with poorly controlled asthma who used the device have been published online by… Read more . . .
-
Aerobit, a smart inhaler company founded in the UK in June 2016 by Ali Molyed, who previously founded payment automation company AccessPay, has announced an agreement with pharmaceutical bit data analysts Eularis. According to the… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland